Azidus Brasil Pesquisa Científica e Desenvolvimento Ltda. Trials

Azidus Brasil Pesquisa Científica e Desenvolvimento Ltda.	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Silva, Joyce

FDCETCB-III, NCT03127592: Phase III Efficacy and Tolerability Trial of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus Isolated Active Substances in Pain Control After Impacted Third Molar Extraction

Terminated

140

RoW

Fixed Dose Combination, Etodolac, Flancox, Cyclobenzaprine, Miosan

Apsen Farmaceutica S.A.

Pain, Acute

07/22

APS001/2020, NCT04647435: Efficacy and Safety of APSCTC for the Treatment of Postsurgical Pain Due to Third Molar Extraction

Completed

396

RoW

APSCTC, Toragesic®, Tramal®

Apsen Farmaceutica S.A.

Postsurgical Pain, Third Molar Extraction

10/24

SAVE-DH, NCT02728115: Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington's Disease

Active, not recruiting

RoW

Cellavita HD Lower Dose, cellular therapy, mesenchymal stem cells, Cellavita HD Higher dose

Azidus Brasil, Cellavita Pesquisa Científica Ltda, Azidus Brasil Scientific Research and Development Ltda

Huntington Disease

12/22

12/23

Doi, Regina M

Probiatop, NCT05603403: Efficacy And Safety Of In The Treatment Of Digestive Symptoms

Completed

150

RoW

Probiatop, Probiotic, Placebo, Placebo Comparator

Azidus Brasil, Farmoquimica S.A.

Signs and Symptoms, Digestive

03/23

Ferrara, Luciana

NCT06260007: Efficacy and Safety Study of Products Based on Tribulus Terrestris, L. in Men With Oligospermia

Recruiting

204

RoW

Tribulus terrestris, Placebo

Herbarium Laboratorio Botanico Ltda

Oligospermia

02/26

08/26

Boya, NCT06150833: Efficacy and Safety and Pharmacokinetics of IVIG

Not yet recruiting

Boya IVIG, IVIG, BOYA

Azidus Brasil, Boya Bio Pharmaceutical Group Co Ltd

Primary Immunodeficiency Disease

04/25

09/25

Imunoforte, NCT06089122: Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIG

Not yet recruiting

IVIG, Shu Yang IVIG

Azidus Brasil, Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

Primary Immunodeficiency Disease

01/25

06/25

STAR, NCT06097780: Efficacy and Safety of NestaCell® in Huntington's Disease

Not yet recruiting

120

NestaCell®

Azidus Brasil, Cellavita Pesquisa Científica Ltda

Huntington Disease

09/25

02/26

NCT05354024: Phase II/III Randomized Clinical Trial of Booster Dose of COVID-19 (Recombinant, Inactivated) Vaccine

Completed

2/3

4400

RoW

NDV-HXP-S 10μg, BNT162b2 30μg

Butantan Institute

Coronavirus Infections, Healthy

10/23

09/24

Macedo, Joyce

ADORE-EXT, NCT04219241: Clinical Extension Study for Safety and Efficacy Evaluation of Cellavita-HD Administration in Huntington's Patients.

Active, not recruiting

2/3

RoW

Cellavita-HD, cellular therapy, mesenchymal stem cells

Azidus Brasil, Cellavita Pesquisa CientÃfica Ltda

Huntington Disease

12/22

Diaz, Ricardo

NCT05779020: Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children .

Active, not recruiting

1373

RoW

Quadrivalent Influenza Vaccine (split virion, inactivated), Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Victoria lineage, Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Yamagata lineage

Butantan Institute, Fundação Butantan

Influenza, Human

09/24

08/25

DOVETAIL, NCT06497465: Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment

Not yet recruiting

150

RoW

Dolutegravir 50mg Tab, TIVICAY 50 mg, TIVICAY PD, Dolutegravir/Lamivudine 50 MG-300mg Oral Tablet [DOVATO], Dolutegravir plus Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC)

Johns Hopkins University, ViiV Healthcare

Tuberculosis, HIV

01/28

01/29

NCT05354024: Phase II/III Randomized Clinical Trial of Booster Dose of COVID-19 (Recombinant, Inactivated) Vaccine

Completed

2/3

4400

RoW

NDV-HXP-S 10μg, BNT162b2 30μg

Butantan Institute

Coronavirus Infections, Healthy

10/23

09/24

NCT05218356: Phase IIa Randomized Placebo Controlled Clinical Study of Codivir in Hospitalized Patients with Moderate COVID-19

Recruiting

130

RoW

Covidir injections, Experimental drug administration, Quantitative PCR SARS-CoV-2, IgM and IgG dosage, Screening Blood tests, Electrocardiogram, ECG, NEWS-2 score, WHO score, Physical examination, COVID-19-Related Symptoms assessment

Code Pharma

COVID-19

12/24

07/25

NCT06799650: Clinical Trial of Gammora® Plus Antiretroviral Treatment for HIV

Recruiting

RoW

Gammora®, Tenofovir, 3TC, Darunavir, Ritonavir

Federal University of São Paulo, Code Pharma

HIV Seropositivity

02/25

03/25

NCT06805656: Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Antiretrovirals

Not yet recruiting

N/A

RoW

Maraviroc, Selzentry, Celsentri, Dolutegravir, Tivicay, Dendritic Cell Vaccine, DC Vaccine, Auranofin, Gold Salt, Sirtuin Histone deacetylase inhibitor, Nicotinamide

Federal University of São Paulo, Conselho Nacional de Desenvolvimento Científico e Tecnológico

Hiv, HIV I Infection

07/26

12/27

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Silva, Joyce

Terminated

140

RoW

Fixed Dose Combination, Etodolac, Flancox, Cyclobenzaprine, Miosan

Apsen Farmaceutica S.A.

Pain, Acute

07/22

APS001/2020, NCT04647435: Efficacy and Safety of APSCTC for the Treatment of Postsurgical Pain Due to Third Molar Extraction

Completed

396

RoW

APSCTC, Toragesic®, Tramal®

Apsen Farmaceutica S.A.

Postsurgical Pain, Third Molar Extraction

10/24

SAVE-DH, NCT02728115: Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington's Disease

Active, not recruiting

RoW

Cellavita HD Lower Dose, cellular therapy, mesenchymal stem cells, Cellavita HD Higher dose

Azidus Brasil, Cellavita Pesquisa Científica Ltda, Azidus Brasil Scientific Research and Development Ltda

Huntington Disease

12/22

12/23

Doi, Regina M

Probiatop, NCT05603403: Efficacy And Safety Of In The Treatment Of Digestive Symptoms

Completed

150

RoW

Probiatop, Probiotic, Placebo, Placebo Comparator

Azidus Brasil, Farmoquimica S.A.

Signs and Symptoms, Digestive

03/23

Ferrara, Luciana

NCT06260007: Efficacy and Safety Study of Products Based on Tribulus Terrestris, L. in Men With Oligospermia

Recruiting

204

RoW

Tribulus terrestris, Placebo

Herbarium Laboratorio Botanico Ltda

Oligospermia

02/26

08/26

Boya, NCT06150833: Efficacy and Safety and Pharmacokinetics of IVIG

Not yet recruiting

Boya IVIG, IVIG, BOYA

Azidus Brasil, Boya Bio Pharmaceutical Group Co Ltd

Primary Immunodeficiency Disease

04/25

09/25

Imunoforte, NCT06089122: Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIG

Not yet recruiting

IVIG, Shu Yang IVIG

Azidus Brasil, Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

Primary Immunodeficiency Disease

01/25

06/25

STAR, NCT06097780: Efficacy and Safety of NestaCell® in Huntington's Disease

Not yet recruiting

120

NestaCell®

Azidus Brasil, Cellavita Pesquisa Científica Ltda

Huntington Disease

09/25

02/26

NCT05354024: Phase II/III Randomized Clinical Trial of Booster Dose of COVID-19 (Recombinant, Inactivated) Vaccine

Completed

2/3

4400

RoW

NDV-HXP-S 10μg, BNT162b2 30μg

Butantan Institute

Coronavirus Infections, Healthy

10/23

09/24

Macedo, Joyce

ADORE-EXT, NCT04219241: Clinical Extension Study for Safety and Efficacy Evaluation of Cellavita-HD Administration in Huntington's Patients.

Active, not recruiting

2/3

RoW

Cellavita-HD, cellular therapy, mesenchymal stem cells

Azidus Brasil, Cellavita Pesquisa CientÃfica Ltda

Huntington Disease

12/22

Diaz, Ricardo

NCT05779020: Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children .

Active, not recruiting

1373

RoW

Butantan Institute, Fundação Butantan

Influenza, Human

09/24

08/25

DOVETAIL, NCT06497465: Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment

Not yet recruiting

150

RoW

Dolutegravir 50mg Tab, TIVICAY 50 mg, TIVICAY PD, Dolutegravir/Lamivudine 50 MG-300mg Oral Tablet [DOVATO], Dolutegravir plus Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC)

Johns Hopkins University, ViiV Healthcare

Tuberculosis, HIV

01/28

01/29

NCT05354024: Phase II/III Randomized Clinical Trial of Booster Dose of COVID-19 (Recombinant, Inactivated) Vaccine

Completed

2/3

4400

RoW

NDV-HXP-S 10μg, BNT162b2 30μg

Butantan Institute

Coronavirus Infections, Healthy

10/23

09/24

NCT05218356: Phase IIa Randomized Placebo Controlled Clinical Study of Codivir in Hospitalized Patients with Moderate COVID-19

Recruiting

130

RoW

Code Pharma

COVID-19

12/24

07/25

NCT06799650: Clinical Trial of Gammora® Plus Antiretroviral Treatment for HIV

Recruiting

RoW

Gammora®, Tenofovir, 3TC, Darunavir, Ritonavir

Federal University of São Paulo, Code Pharma

HIV Seropositivity

02/25

03/25

NCT06805656: Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Antiretrovirals

Not yet recruiting

N/A

RoW

Maraviroc, Selzentry, Celsentri, Dolutegravir, Tivicay, Dendritic Cell Vaccine, DC Vaccine, Auranofin, Gold Salt, Sirtuin Histone deacetylase inhibitor, Nicotinamide

Federal University of São Paulo, Conselho Nacional de Desenvolvimento Científico e Tecnológico

Hiv, HIV I Infection

07/26

12/27



	Diseases Companies Products Productz Mechanisms of Action Sites